CD8A and infection: Clinical failure of a promising T-cell based HIV-1 vaccine in a phase IIb human trial (STEP) [1] has prompted a re-evaluation of the mechanisms of immunity, because tests of T-cell based vaccines against SIV in macaques have indicated that virus-specific CD8+ T lymphocytes (CTLs) can ameliorate or even prevent infection.